Primer and method for CYP2D6 genetic typing detection
Through multiple pairs of primers, multiple PCR and Pacific Biosciences HiFi sequencing technology, the accuracy and sequencing length of CYP2D6 genotyping detection are solved, and genotyping detection with high coverage and high sensitivity is achieved, supporting individualized treatment. Precise medication.
Patent Information
- Application Number
- CN202411132138.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-16
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2044-08-16
AI Technical Summary
The existing CYP2D6 genotyping detection technology has problems such as low accuracy, insufficient sequencing length, and inability to effectively distinguish haplotypes, copy number variations and homologous genes, resulting in inaccurate guidance on individualized medications and affecting the efficacy and safety of the drug.
Using multiple pairs of primers, one tube multiple PCR method combined with Pacific Biosciences' HiFi sequencing technology, specific amplification primers were designed for CYP2D6 genotyping detection, and high coverage and high sensitivity were achieved through PCR amplification, library construction and magnetic bead purification. Genotype detection.
The complete sequence acquisition of the CYP2D6 gene is achieved, the resolution and accuracy are improved, the new alleles can be completely detected and the haplotypes can be distinguished, the human, material and financial investment is reduced, and the precise medication for individualized treatment is supported.
Smart Images

Figure CN119061132A_ABST
Abstract
Description
Technical Field
[0001] The present application relates to the technical field of genotyping detection, and in particular to a primer and method for CYP2D6 genotyping detection. Background Art
[0002] CYP2D6 (Cytochrome P4502D6) is an enzyme encoded by the CYP2D6 gene. The content of this enzyme in the liver accounts for only 2-9% of the total P450 liver protein, but it is involved in the metabolism of about 20-30% of commonly used drugs, including antidepressants, antiarrhythmic drugs, antipsychotics and analgesics. The activity of CYP2D6 enzyme varies greatly between different individuals, which is mainly affected by the transcription coding of the CYP2D6 gene, resulting in large differences in its function. The CYP2D6 gene is highly polymorphic, including single nucleotide polymorphisms (SNPs), insertions / deletions (Indels), copy number variations (CNVs), structural variations (SVs), and fusions with adjacent homologous CYP2D7 pseudogenes. Currently, more than 300 CYP2D6 alleles are included in the drug gene variation PharmVar database. Different allele variations cause differences in enzyme activity and enzyme quantity. The enzyme activity of the encoded protein is expressed as missing, reduced, normal or increased, which in turn affects the efficacy of medication. Detection of single nucleotide polymorphisms, oligonucleotide insertions and deletions of the CYP2D6 gene can detect the absence and reduction of CYP2D6 enzyme activity, and detection of copy number increase and gene deletion of the CYP2D6 gene can detect the increase and decrease of CYP2D6 enzyme activity. By detecting CYP2D6 gene variation, the pharmacokinetic properties of candidate drugs in vivo and their metabolites can be predicted, and studying the activity and toxicity of these metabolites will also help us find a safer, more reasonable and effective genetic molecular mechanism of oxidative metabolism polymorphism of the CYP2D6 enzyme system. Therefore, comprehensive detection of CYP2D6 gene variation is of great significance in clinical application. However, due to frequent copy number variation (CNV) and highly homologous pseudogenes, accurate CYP2D6 allele typing has been proven to be challenging, and the current detection methods for comprehensive detection of CYP2D6 gene variation are costly and unreliable, which makes many researchers unable to do so. At the same time, due to economic reasons, the development of genetic testing for personalized treatment has been slow.
[0003] In recent years, with the innovation of technology, genotyping has become increasingly common. Currently, the representative CYP2D6 gene detection and typing technologies are mainly the following:
[0004] 1.PCR sequence specific primer analysis (PCR-sequence specific primer, PCR-SSP);
[0005] The operating principle of this method is to design sequence-specific primers whose first base at the 3′ end matches the specific base of each allele according to the base specificity that determines the CYP2D6 allele. During the PCR reaction, the DNA fragment can be completely replicated only when the first base at the 3′ end of the primer is complementary to the base that determines the specific allele. The results are detected by agarose gel electrophoresis to detect the presence or absence of PCR products for allele typing. This method is characterized by simple operation, low experimental cost, short timeliness, an initial interpretation of the results, and can only analyze known specific alleles, but cannot detect new alleles, and cannot be well distinguished from the CYP2D7 gene with higher homology, and there will be many false positive and false negative phenomena.
[0006] 2. Nucleic acid sequencing technology (PCR-Sequencing-Based Typing; PCR-SBT)
[0007] That is, the Sanger first-generation sequencing technology. This method mainly uses PCR to amplify specific fragments of the CYP2D6 gene, and performs DNA sequencing on the PCR product to analyze its allele type. The first-generation sequencing can directly obtain the gene sequence information of the relevant region through sequencing, and the accuracy of typing can be improved, and even new alleles can be directly discovered. Since the Sanger first-generation sequencing technology can only obtain 600-800bp of sequence information at a time, and the full length of the CYP2D6 gene is about 5.4Kb, if all CYP2D6 gene information is to be obtained, primers and sequencing are required for multiple positions, which leads to high costs and complicated operations. Due to the limitations of this method, the haplotype of the sample cannot be distinguished, so multi-SNP joint mutations, copy number variations, gene deletions, and recombination with highly homologous genes cannot be well distinguished, which will lead to ambiguous results for heterozygous samples and cannot be accurately typed.
[0008] 3. Next Generation Sequencing (NGS)
[0009] At present, the NGS sequencing platform of Illumina is the main one in the market. This technology connects specific oligonucleotide sequences (i.e., adapters) at both ends of the CYP2D6 gene product, and loads the product onto a flowcell with a complementary adapter sequence on the surface. It replicates DNA through a bridge polymerase chain reaction, amplifies the signal, and converts the light signal into a base sequence to achieve high-speed and high-throughput sequencing. This method has a large throughput, so the cost per sample is relatively low, and new alleles can be discovered; however, this technology can only obtain a length of 150-250bp, resulting in the original sequence obtained by sequencing needing to be further assembled to obtain complete CYP2D6 gene information, and this process needs to be calculated by statistical methods, which cannot distinguish haplotypes well, so it cannot completely solve exon joint mutations, copy number variations, gene deletions, homologous gene exchanges, etc., so some ambiguous and erroneous results are often obtained.
[0010] Due to the complexity of CYP2D6 genotyping and the limitations of existing common detection technologies, it is impossible to quickly and accurately perform genotyping. The inaccurate and ambiguous results may mislead individualized medication guidance, causing patients to take too much or too little medication and fail to achieve the best therapeutic effect. Therefore, based on accurate genotyping results, the clinic can be guided to select appropriate drugs and dosages to maximize the efficacy and safety of the drugs. Therefore, we are trying to develop new technologies to break the defects and bottlenecks of other methods and make CYP2D6 genotyping more accurate and sensitive.
[0011] Although the PCR-SSP method has the advantages of simple operation, low experimental cost, short time and easy analysis, it is unable to detect new alleles and typing, and the types of alleles detected are limited. If too many tests are performed, the experimental workload will be huge, and the corresponding labor costs and reagent costs will also increase exponentially. The experimental results are also due to the problem of detection site specificity, and the difficulty of primer design increases; PCR-SBT also has the advantages of simple operation, low experimental cost, short time and easy analysis. It can detect new alleles, but it is also unable to type. Due to technical limitations, it can only amplify exons as the mainstream, so the variants produced by multi-exon combined mutations cannot be well distinguished, resulting in ambiguous results; NGS technology can detect new allele advantages, but due to the problem of read length, the assembly is very dependent on data calculation. The assembly of more small fragments will introduce a large number of ambiguous results, especially when gene recombination occurs, which brings more confusion to the assembly.
[0012] At present, gene sequencing technology has steadily entered the latest third-generation sequencing technology (Third Generation Sequencing; TGS), and its gene sequence reading length is more than 10,000bp, which is much higher than SBT and NGS. We chose to use Pacific Biosciences' sequencing technology platform, whose HiFi sequencing mode can achieve the data accuracy of QV30 (99.9%), and the length of a single subread can reach 15-50kb. It effectively solves the shortcomings of traditional sequencing methods, such as low accuracy and short sequencing length. The complete CYP2D6 gene sequence or missing or recombined sequence can be obtained without assembly, and the resolution and accuracy are effectively improved. At present, there are no products based on Pacific Biosciences technology applied to CYP2D6 genotyping detection on the market, so we have developed a series of CYP2D6 genotyping processes through its technical advantages. Summary of the invention
[0013] The present invention provides a multiplex PCR method using multiple pairs of primers in one tube for CYP2D6 genotyping detection, which can accurately distinguish genes with high homology and improve the high coverage, sensitivity and accuracy of CYP2D6 genotyping detection primers and method for CYP2D6 genotyping detection.
[0014] The present application is realized by the following technical scheme, a detection primer for CYP2D6 genotyping, comprising: the specific amplification primer sequence of the CYP2D6 gene is as follows:
[0015] Upstream primer CYP2D6-1-F2: GATGCCTTGAGGTCGTCTTCTTTGG;
[0016] Downstream primer CYP2D6-1-R2: CACGGGCGATAATGTGGCAACTC;
[0017] Upstream primer CYP2D6-2-F1: GGGAGAAAGGAGTAAAGGAATAGTTGAAGAAT;
[0018] Downstream primer CYP2D6-2-R1: CAAAGGTTGGTGTTGAGAAGTCTGATGAAT.
[0019] A method for CYP2D6 genotyping detection, comprising:
[0020] PCR amplification of CYP2D6 gene fragment;
[0021] The obtained target PCR products were used to construct a third-generation sequencing library;
[0022] Purify the established library with magnetic beads;
[0023] Mix the purified library;
[0024] Take the mixed library and sequence it.
[0025] Preferably, the method for PCR amplification of the CYP2D6 gene comprises:
[0026] Design specific amplification primers for the CYP2D6 gene. The sequences of the specific amplification primers for the CYP2D6 gene are as follows:
[0027] Upstream primer CYP2D6-1-F2: GATGCCTTGAGGTCGTCTTCTTTGG;
[0028] Downstream primer CYP2D6-1-R2: CACGGGCGATAATGTGGCAACTC;
[0029] Upstream primer CYP2D6-2-F1: GGGAGAAAGGAGTAAAGGAATAGTTGAAGAAT;
[0030] Downstream primer CYP2D6-2-R1: CAAAGGTTGGTGTTGAGAAGTCTGATGAAT;
[0031] The primers are synthesized, and the 5′ bases are phosphorylated during the synthesis;
[0032] mixing the synthesized primers to obtain a primer mixture;
[0033] Add PCR amplification system reagents to the primer mixture to perform PCR amplification.
[0034] Preferably, the method for constructing a library comprises:
[0035] Barcode adapter dilution: Use TE buffer to dilute the dry powder Barcode adapter to a concentration of 100uM;
[0036] Barcode annealing: anneal the single-stranded Barcode adapter into a double-stranded one;
[0037] Adapter ligation reaction, connect a unique barcode adapter to each sample;
[0038] Exonuclease digestion reaction removes products of failed adapter ligation and obtains high-quality library.
[0039] Preferably, the method for purifying the established library comprises:
[0040] Use 0.45* magnetic beads to purify the exonuclease digestion products, remove reagents in the library construction process and remove small fragment sequences to obtain high-quality libraries; use Qubit to quantify single-sample libraries.
[0041] The beneficial effects of this application are:
[0042] It effectively solves the shortcomings of traditional sequencing methods, such as low accuracy and short sequencing length. The complete CYP2D6 gene sequence or deleted or recombined sequence can be obtained without assembly, and the resolution and accuracy can be effectively improved. It can completely detect new alleles, distinguish haplotypes, and accurately type, making all types of typing invisible. At the same time, this solution has a large detection throughput, and multiple samples can be tested simultaneously. The experimental process can be automated, greatly reducing manpower, material and financial resources. BRIEF DESCRIPTION OF THE DRAWINGS
[0043] In order to more clearly illustrate the embodiments of the present application or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present application. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.
[0044] Figure 1 It is a diagram of the product of the CYP2D6 gene;
[0045] Figure 2 It is a schematic diagram of the two haplotypes of NA17221 in the embodiment of the present application;
[0046] Figure 3 It is a schematic diagram of two haplotype typing of sample No. 2 in the embodiment of the present application; DETAILED DESCRIPTION
[0047] Example embodiments will now be described more fully with reference to the accompanying drawings. However, example embodiments can be implemented in a variety of forms and should not be construed as limited to the examples set forth herein; rather, these embodiments are provided so that this application will be more comprehensive and complete and fully convey the concept of the example embodiments to those skilled in the art.
[0048] A detection primer for CYP2D6 genotyping. The primer in this embodiment is a specific amplification primer for the CYP2D6 gene. The primer synthesis selects 5' phosphorylation. The following is the primer sequence:
[0049]
[0050] / 5Phos / indicates that the 5′ base is phosphorylated during primer synthesis.
[0051] Through primer design, the amplification region extends to the upstream region of the CYP2D7 gene. It can effectively provide complete CYP2D6 gene information. And due to the characteristics of this technology, all CYP2D6 information is obtained (including exon regions and intron regions). At present, most CYP2D6 genotyping only needs to use exon region information, and the technology in the embodiment can provide more comprehensive intron information, as well as the flanking sequences of the gene deletion region or the region that may be recombined with CYP2D7, clarify the common copy number variation, perfectly distinguish haplotypes, and provide a complete solution for further studying the function of the CYP2D6 gene in the future, which is not available in traditional technologies.
[0052] This embodiment also provides a method for CYP2D6 genotyping detection, comprising:
[0053] PCR amplification of CYP2D6 gene fragment;
[0054] The amplification method used in this embodiment includes:
[0055] Design specific amplification primers for the CYP2D6 gene, and select 5' phosphorylation during primer synthesis. The following is the primer sequence.
[0056] primer Sequence(5′-3′) CYP2D6-1-F2 / 5Phos / GATGCCTTGAGGTCGTCTTCTTTGG CYP2D6-1-R2 / 5Phos / CACGGGCGATAATGTGGCAACTC CYP2D6-2-F1 / 5Phos / GGGAGAAAGGAGTAAAGGAATAGTTGAAGAAT CYP2D6-2-R1 / 5Phos / CAAAGGTTGGTGTTGAGAAGTCTGATGAAT
[0057] Note: / 5Phos / indicates that the 5′ base is phosphorylated during primer synthesis.
[0058] Primer mix system
[0059] The synthesized primer powder was centrifuged at high speed before use, and diluted to the working solution concentration using EB buffer. The diluted primers were prepared into primer MIX according to the system in the table below.
[0060]
[0061] After preparing the primer MIX, add the reagents listed in the PCR amplification system in the table below to the reaction tube in sequence, close the tube cap, mix well, and centrifuge.
[0062] Reagent name Volume of single sample added (uL) 2×PCR Buffer for KOD FX Neo 12.5 dNTPs(2mM) 5 Primer Mix 0.16 KOD Neo FX 0.5 DNase / RNase-Free Deionized Water 6.84-X gDNA X(50ng) Total 25
[0063] Set the PCR instrument program according to the parameters in the table below for amplification: hot cover: 105℃, heating and cooling rate: 6.0℃ / S
[0064]
[0065] PCR product quality inspection: Use 1% agarose gel electrophoresis to detect and analyze the PCR reaction products to determine whether the target gene is amplified. Voltage: 150V Time: 50min, the figure below is an example of amplification results. (5ul amplification product + 5ul6× loading buffer for gel running).
[0066] Library construction
[0067] 1. Barcode preparation
[0068] 1) Barcode adapter dilution
[0069] Centrifuge the dry powder tube of Barcode adapter at 10000rpm for 5min, add a certain volume of TE buffer to dilute the dry powder Barcode to a concentration of 100uM, shake and mix, and centrifuge instantly; a total of 96 Barcode adapters, the sequence types are shown in the following table:
[0070]
[0071] Note:
[0072] a. The Barcode adapter sequence information is provided by Pacbio. / 5Phos / indicates that the 5′ base of the Barcode is phosphorylated during synthesis.
[0073] b. The underlined ones are Barcode sequences.
[0074] 2) Barcode annealing
[0075] Prepare 10×annealing buffer according to the table below, and use 10×annealing buffer and RNAaseFreeWater to dilute the diluted 100uM Barcode adapter solution 5 times, vortex to mix and centrifuge instantly, then place the mixed solution on a PCR instrument and anneal the single-stranded Barcode adapter into a double-stranded one according to the following annealing program. After the annealing program is completed, immediately place the product on ice for 5 minutes and then store it at -20℃.
[0076] a.10×annealing buffer ingredients
[0077] Tris-HCl, pH 7.5 100mM NaCl 1M RNAase Free Water Supplement system
[0078] b. Annealing system
[0079]
[0080] c. Annealing procedure
[0081] The annealing temperature was gradually decreased by 5°C.
[0082]
[0083]
[0084] 2. Adapter ligation reaction
[0085] 1) Prepare the adapter ligation reaction MIX on ice according to the following table:
[0086] Reagents Volume of single sample added (uL) 10×T4 DNA Ligase Buffer 1.5 dNTP Mix (10 mM each) 0.1 dATP (100 mM) 0.1 T4 DNA Polymerase 0.3 T4 Polynucleotide Kinase 0.3 T4 DNA Ligase (Rapid) 1.25 Total 3.55
[0087] 2) The following table shows the connection system: Add the materials listed in order, cover the tube, mix well and centrifuge.
[0088] Amplification products 8.95μL (200~300ng) Barcode connector 2.5μL Ligase Mix 3.55μL Total 15μL
[0089] 3) The following table shows the connection reaction program. After setting the parameters in advance, the connection reaction is carried out. The heated cover is 75°C and the heating and cooling rate is 6°C / S.
[0090] temperature time Number of cycles 37℃ 25min 1× 25℃ 20min 1× 65℃ 10min 1× 4℃ ∞
[0091] 2. Exonuclease digestion reaction
[0092] 1) Exonuclease system: Incorrect ligation may occur during the ligation process, so the incorrect ligation product is digested by exonuclease. Prepare exonuclease MIX on ice according to the table below. After the ligation reaction is completed, place it on ice, add 2ul exonuclease MIX to each tube, cover the tube, mix well, and centrifuge.
[0093] Reagent name Volume of single sample added (uL) Exonuclease| 1.5μL Exonuclease||| 0.5μL Total 2μL
[0094] 2) Exotomy procedure: The following table shows the digestion reaction parameters. Set them in advance and perform the digestion reaction. Heat cover: 45°C, heating and cooling rate: 6°C / s
[0095] temperature time Number of cycles 37℃ 60min 1× 4℃ ∞
[0096] After the digestion reaction is completed, magnetic bead purification must be performed as soon as possible.
[0097] Library purification
[0098] 1. Take out the VAHTSTM DNA Clean Beads (hereinafter referred to as magnetic beads) from the refrigerator half an hour in advance, place them on a vertical mixer and slowly mix them at room temperature for 30 minutes;
[0099] 2. Add the digested product to the PCR tube, add 1 volume of DNase / RNase-Free Deionized Water (a deionized water that does not contain DNase and RNase), and then add 15.3 μL of magnetic beads (0.45x). Mix by flicking or shaking at a low speed. Leave at room temperature for 10 minutes, flicking 2-3 times to mix.
[0100] 3. Centrifuge the PCR tube (collect the liquid in the tube to the bottom of the tube through short-term high-speed centrifugation), then place it on the magnetic rack to adsorb the magnetic beads for 10 minutes. During this period, prepare 70% alcohol. The alcohol needs to be prepared before use.
[0101] 4. Discard the supernatant, then add 200 μL of 70% alcohol along the opposite side of the tube where the magnetic beads are adsorbed. Be careful not to disperse the magnetic beads when adding alcohol.
[0102] 5. Repeat the previous step and perform alcohol cleaning for the second time;
[0103] 6. Discard the alcohol, centrifuge the PCR tube, put it back on the magnetic stand, and discard the residual liquid;
[0104] 7. Open the PCR tube and dry it for no more than 30 seconds, then add 12μL EB Buffer;
[0105] 8. Gently flick the beads to mix them evenly. Keep the beads in a mixed state and place them at room temperature for 10 minutes, flicking them 2-3 times during the process.
[0106] 9. Separate the PCR tube instantly, then place it on a magnetic rack to adsorb the magnetic beads for 10 minutes;
[0107] 10. Transfer 10 μL of supernatant to a new PCR tube;
[0108] 11. Use Qubit to quantify the single sample library, and take 6ng pooling of the same mass for each single sample library as a mixed library.
[0109] Mixed Database
[0110] 1. Use a gun to measure the exact volume x μL (> 400 ng) of the mixed library, and add x*0.6 μL magnetic beads (0.6x) to it; the purification process is the same as the library purification process, and finally 50 μL EB is used to elute the library;
[0111] 2. Take x μL (>200 ng) of the library obtained in the previous process, add x*0.45 μL magnetic beads (0.45x) to it; the purification process is the same as the library purification process, and finally use 20 μL EB to elute the library;
[0112] 3. Use Qubit to quantify the final library. Three replicates are required and the average is taken as the final library concentration. The final library concentration is required to be higher than 3ng / μL.
[0113] 4. Use 5200 Fragment Analyzer System to detect the library and calculate the average fragment size.
[0114] For sequencing, the recommended sequencing volume is 150pM, using the HiFireads mode and an average fragment size of 5000bp.
[0115] Test results, the results after sequencing are as follows Figure 1 As shown, Figure 1 M is the marker point.
[0116] In this embodiment, the sequencing results and operation procedures are described as follows:
[0117] The product obtained by amplification is obtained through the library construction process to obtain a library. The data obtained after the library is sequenced on the machine is converted into high-accuracy HiFi data, and then the mutation site information and structural variation information are obtained through data analysis. Finally, it is compared with the standard database to obtain the corresponding typing or obtain a new typing. The sample types sequenced are listed in the following table. The following table only gives examples of representative haplotype types. The patent of this invention can detect various typings such as those listed in the pharmvar database and new typings not included in the pharmvar database. Examples and test results are as follows:
[0118]
[0119]
[0120] Among them: This embodiment provides a typical sequence table of partial sequencing of sample NA17221 and sample No. 16 as an example.
[0121] The sequence table of the sequencing sequence of the NA17221 sample includes NA17221 sample haplotype 1: copy1 sequence CYP2D6*1 typing; NA17221 sample haplotype 1: copy2 sequence CYP2D6*1 typing, NA17221 sample haplotype 2 sequence: CYP2D6*2 typing; the underlined part in the sequence table of NA17221 sample haplotype 1 is the DUP region; Figure 2 Schematic diagram of the two haplotypes of NA17221.
[0122] The sequencing sequence table of sample No. 16 includes the sequence of haplotype 1 of sample No. 16: CYP2D6*5 typing, and the sequence of haplotype 2 of sample No. 6: CYP2D6*5 typing, where the underlined part is the deletion region of the CYP2D6 gene; Figure 3 Schematic diagram of the two haplotype deletion regions of the CYP2D6 gene.
[0123] In this embodiment, for samples with two complete haplotypes, the full-length sequences of two complete haplotypes can be obtained at one time and the corresponding typing (including whether the mutation site is a single SNP or multiple SNPs) can be given;
[0124] For samples with one haplotype missing and one haplotype complete, the flanking sequence of one haplotype missing sequence and the full-length sequence of another haplotype complete can be obtained at one time, and the corresponding typing (including whether the mutation site is a single SNP or multiple SNPs) can be given;
[0125] For samples with 2 haplotype deletions, the flanking sequences of the 2 haplotype deletion sequences can be obtained at one time and the corresponding typing can be given;
[0126] For samples with copy number variation, the total copy number of sequences in the range of 2-5N can be obtained at one time, and the copy number on the haplotype can be distinguished and the corresponding typing can be given; (e.g., the copy number of haplotype 1 is 2N, and the copy number of haplotype 2 is 3N; e.g., the copy number of haplotype 1 is 1N, and the copy number of haplotype 2 is 3N; etc.)
[0127] For samples that have recombined with the homologous gene CYP2D7, the recombinant sequence can be obtained at one time and the corresponding typing can be given.
[0128] Here is the sequence mentioned above:
[0129] NA17221 sample haplotype 1: copy 2 sequence CYP2D6*1 typing
[0130] DUP Area
[0131]
[0132]
[0133] Haplotype 1 sequence of sample 16: CYP2D6*5 typing
[0134] CAAAGGTTGGTGTTGAGAAGTCTGATGAATATTGAATTCCTGAAGCTCAGACTTTTTTCTCTCTGGAAGTTTTTGGGTTCCACTCTGTCCTCAGTGTTGTGAAATTTCTTGACAACAAAATTGGGGCTGGGTCCCCTTCATTCATTGTCATGAACACTTGGTGTTTCCTTCTCTACTGGAAACTCATGTTCTTCCTCTGTGAGAACTTGTCTTGACAAAAAAGAAACGTATTTATTAGACATCTTTCCTTGCCTCCTAGTCTGTTGTCTCTGCTGCCTGTTTCAGAAACATCTAAACAACAATTTAGCTGTTGGAGCTCCTGACCTCTTCTCTGTTCTTTCTGGAAAATATTTTTTTCAAGTTTAGCTTCTATACTTTGATTAGATTTTGCATTCCTATTATTATATTTTTTATTTTTAAGGCAAGGTCTTTCTCTGTTGCCCAGGCTGGAGTGCAGTGGCACGATCACAGTTCACTGCAGCTTTGTTCCTGGACTCAAGTGATCCTCCCACCTCAGCCTCCCAAGCAGCTGGAACTACAGGTGTGTGCCACCACACCCAGCCAGTATTTTAATTTTTTGTAGAGATGGGGTCTCCTTAGGTGGCCCAGGCTGGTGTTGAATTCCTAGGCTCAAACAATCCTCCTGCCTTAGCCTCCCAAAATGCTGGGATTACAGGCATGAGCTAAGGCACCCAGACTATATTTTTGTCAAGAATTAGTGGTGGTGGGTGTTTGAACATTTTTATTTTAGACCCTCCTATTCTTATTTCATGAATGCAAAGTTTTATCTTTCTAAAGATATCAATTATAGATTTTTTTTTTAAGACAGTTTCACTCTTGTTGACCAGGCTGGAGTGCAATGATGCGATCTCGGCTCACTGCAGCCTCTGCCTCCCAGGTTCAAGCAATTCTCCTGCCTCAGCCTCCTGAGTAGCTG CYP2D6 gene deletion region
[0135] This technical solution takes advantage of the long length and high accuracy of Pacific Biosciences' third-generation sequencing to fully detect new alleles, distinguish haplotypes, and accurately type, making all types of typing invisible; at the same time, this solution has a large detection throughput, multiple samples can be tested simultaneously, and the experimental process can be automated, greatly reducing manpower, material and financial resources.
[0136] Those skilled in the art will readily appreciate other embodiments of the present application after considering the specification and practicing the embodiments disclosed herein. The present application is intended to cover any variations, uses or adaptations of the present application, which follow the general principles of the present application and include common knowledge or customary technical means in the art that are not disclosed in the present application.
[0137] It should be understood that the present application is not limited to the precise structures that have been described above and shown in the drawings, and that various modifications and changes may be made without departing from the scope thereof. The scope of the present application is limited only by the appended claims.
Claims
1. A detection primer for CYP2D6 genotyping, characterized in that: include: The specific amplification primer sequences for the CYP2D6 gene are as follows: Upstream primer CYP2D6-1-F2: GATGCCTTGAGGTCGTCTTCTTTGG; Downstream primer CYP2D6-1-R2: CACGGGCGATAATGTGGCAACTC; Upstream primer CYP2D6-2-F1: GGGAGAAAGGAGTAAAGGAATAGTTGAAGAAT; Downstream primer CYP2D6-2-R1: CAAAGGTTGGTGTTGAGAAGTCTGATGAAT.
2. A method for CYP2D6 genotyping detection, characterized in that: include: PCR amplification of CYP2D6 gene fragment; The obtained target PCR products were used to construct a third-generation sequencing library; Purify the established library with magnetic beads; Mix the purified library; Take the mixed library and sequence it.
3. A method for CYP2D6 genotyping detection according to claim 2, characterized in that: Methods for PCR amplification of the CYP2D6 gene include: Design specific amplification primers for the CYP2D6 gene. The sequences of the specific amplification primers for the CYP2D6 gene are as follows: Upstream primer CYP2D6-1-F2: GATGCCTTGAGGTCGTCTTCTTTGG; Downstream primer CYP2D6-1-R2: CACGGGCGATAATGTGGCAACTC; Upstream primer CYP2D6-2-F1: GGGAGAAAGGAGTAAAGGAATAGTTGAAGAAT; Downstream primer CYP2D6-2-R1: CAAAGGTTGGTGTTGAGAAGTCTGATGAAT; The primers are synthesized, and the 5′ bases are phosphorylated during the synthesis; mixing the synthesized primers to obtain a primer mixture; Add PCR amplification system reagents to the primer mixture to perform PCR amplification.
4. A method for CYP2D6 genotyping detection according to claim 2, characterized in that: Methods for constructing libraries include: Barcode adapter dilution: Use TE buffer to dilute the dry powder Barcode adapter to a concentration of 100uM; Barcode annealing: anneal the single-stranded Barcode adapter into a double-stranded one; Adapter ligation reaction, connect a unique barcode adapter to each sample; Exonuclease digestion reaction removes products of failed adapter ligation and obtains high-quality library.
5. A method for CYP2D6 genotyping detection according to claim 4, characterized in that: Methods for purifying the established library include: Use 0.45* magnetic beads to purify the exonuclease digestion products, remove reagents in the library construction process, and remove small fragment sequences to obtain a high-quality library; Quantification of single sample libraries using Qubit.
Citation Information
Patent Citations
Long-range PCR (Polymerase Chain Reaction) method and kit for detecting polymorphism variation of CYP2D6 gene
CN113186265A
Library establishment kit for detecting polymorphism of pharmacogenomics related gene CYP2D6 and application of library establishment kit
CN116875678A
